FMR LLC reports 12% stake in VOR Biopharma
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
VOR Biopharma Inc’s common stock is reported as beneficially owned by investment manager FMR LLC and by Abigail P. Johnson on a Schedule 13G/A. FMR LLC and Johnson each report beneficial ownership of 6,509,996 shares of VOR Biopharma common stock, representing 12.0% of the class. FMR LLC reports 6,509,263 shares with sole voting power and the full 6,509,996 shares with sole dispositive power, with no shared voting or dispositive power. One or more other persons have rights to dividends or sale proceeds from these shares, but no such person holds more than five percent of VOR Biopharma’s outstanding common stock.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
Sole Dispositive Power financial
Schedule 13G regulatory
parent holding company financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of VOR (VOR Biopharma Inc) does FMR LLC report owning in this Schedule 13G/A?
Does any other investor hold more than 5% of VOR (VOR Biopharma Inc) through FMR-managed accounts?
Why is this Schedule 13G/A filing for VOR (VOR Biopharma Inc) structured as a parent holding company report?
AI-generated analysis. How Rhea-AI works. Not financial advice.